159 related articles for article (PubMed ID: 34386895)
21. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human thyrotropin in the management of thyroid cancer.
McDougall IR; Weigel RJ
Curr Opin Oncol; 2001 Jan; 13(1):39-43. PubMed ID: 11148684
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.
Incerti C
J Endocrinol Invest; 1999; 22(11 Suppl):8-16. PubMed ID: 10727000
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
25. The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer.
Sherman SI
Endocr Pract; 2013; 19(1):157-61. PubMed ID: 23435044
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Serum Thyroglobulin Measured at 48 Hours Versus 72 Hours after Second Dose of Recombinant Human Thyrotropin in Surveillance of Well-Differentiated Thyroid Cancer.
Haddady S; Pinjic E; Lee SL
Endocr Pract; 2021 Mar; 27(3):216-222. PubMed ID: 33779554
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
[TBL] [Abstract][Full Text] [Related]
28. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.
Chindris AM; Diehl NN; Crook JE; Fatourechi V; Smallridge RC
J Clin Endocrinol Metab; 2012 Aug; 97(8):2714-23. PubMed ID: 22639286
[TBL] [Abstract][Full Text] [Related]
29. Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy.
Taïeb D; Lussato D; Guedj E; Roux F; Mundler O
Thyroid; 2006 Feb; 16(2):177-9. PubMed ID: 16676403
[TBL] [Abstract][Full Text] [Related]
30. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
[TBL] [Abstract][Full Text] [Related]
31. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
32. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
33. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.
Torres MS; Ramirez L; Simkin PH; Braverman LE; Emerson CH
J Clin Endocrinol Metab; 2001 Apr; 86(4):1660-4. PubMed ID: 11297600
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management.
Chen MK; Doddamane I; Cheng DW
Curr Opin Oncol; 2010 Jan; 22(1):6-10. PubMed ID: 19844179
[TBL] [Abstract][Full Text] [Related]
38. [Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].
Liu B; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):588-92. PubMed ID: 22826964
[TBL] [Abstract][Full Text] [Related]
39. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
40. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
